STOCK TITAN

Evaxion announces strategy and business update and third quarter 2026 financial results

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Evaxion (EVAX) is refocusing its research on cancer vaccines and reported a third-quarter 2026 net loss of $3.5 million. The loss narrowed from $3.7 million in the prior quarter but reversed a $4.6 million profit a year earlier. Quarterly revenue fell to zero from $7.492 million a year earlier. Share sales raised $2.2 million in gross proceeds, and Evaxion expects its cash to last toward the end of 2027.

In advanced melanoma, phase 2 data for personalized vaccine EVX-01 showed 89% vaccine target precision and sustained immune and clinical responses at three years. Evaxion says it is on track to file a phase 1 trial application for EVX-04 by year-end 2026 and plans to advance EVX-05 toward clinical development. Future work on infectious disease programs depends on external partner funding.

Loading...
Loading translation...
12 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 11 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.At-the-market share sales raised $2.2 million in gross proceeds; Evaxion expects cash to last toward the end of 2027 9.4% of market cap
  • Moderate pointEVX-01 phase 2 data showed sustained T-cell and clinical responses at three years in advanced melanoma
  • Minor pointEVX-01 vaccine target precision was 89% in the phase 2 advanced melanoma trial
  • Minor point. Forward-looking: it has not happened yet and may not happen.EVX-04 phase 1 trial application is on track for filing before the end of 2026, Evaxion says
  • Minor point. Forward-looking: it has not happened yet and may not happen.EVX-05 is slated to advance toward clinical development under Evaxion’s cancer vaccine refocus
7 minor points
  • Minor point. Forward-looking: it has not happened yet and may not happen.EVX-01 expansion into additional indications is planned through partnerships
  • Minor point. Forward-looking: it has not happened yet and may not happen.Cancer vaccine target discovery will continue under Evaxion’s revised research strategy
  • Minor pointR&D expenses fell to $2.312 million from $3.092 million year over year in Q3 and to $6.943 million from $7.415 million over nine months
  • Minor pointGeneral and administrative expenses fell to $1.361 million from $1.377 million year over year in Q3 and to $4.394 million from $5.295 million over nine months
  • Minor pointTotal liabilities fell to $10.523 million at September 30 from $11.369 million at December 31, 2025
  • Minor pointEVX-B4 vaccine targets reached a preclinical validation milestone
  • Minor point. Forward-looking: it has not happened yet and may not happen.Autoimmune concept validation is planned to support potential future partnerships

Negative

  • Moderate pointQ3 net loss of $3.5 million narrowed from $3.7 million in Q2 2026 but reversed a $4.6 million year-earlier profit
  • Moderate pointQ3 revenue fell to zero from $7.492 million a year earlier, when Evaxion recorded EVX-B3 licensing revenue; nine-month revenue fell to zero from $7.528 million
  • Moderate pointNine-month net loss widened to $10.899 million from $1.789 million a year earlier
  • Moderate pointCash and cash equivalents fell to $13.3 million at September 30 from $14.0 million at June 30, 2026, and $23.234 million at December 31, 2025
  • Moderate pointTotal equity fell to $8.143 million at September 30 from $17.039 million at December 31, 2025
  • Moderate pointAt-the-market issuance of Evaxion shares diluted existing shareholders
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Future infectious disease research will proceed only if funded by external partners
4 minor points
  • Minor pointOperating results swung to a $3.673 million Q3 loss from a $3.022 million profit a year earlier; the nine-month operating loss widened to $11.338 million from $5.182 million
  • Minor pointPer-share results swung to a $0.01 Q3 loss from a $0.01 profit a year earlier; the nine-month loss widened to $0.03 from $0.01, basic and diluted
  • Minor pointQ3 net financial expense was $0.1 million, versus $1.3 million in net financial income a year earlier
  • Minor pointTotal assets fell to $18.665 million at September 30 from $28.408 million at December 31, 2025

News Explained

The EIB filing concerns possible resale of warrant shares, not an issuer capital raise.

The ATM share sales brought $2.2 million in gross proceeds to Evaxion; this program permits gradual sales of new shares at prevailing market prices, which can dilute existing holders.

Separately, the F-1 amendment filed in November concerns only possible resale by the European Investment Bank of shares issuable upon exercise of warrants received in the 2025 debt settlement; the company says it is not conducting a capital raise.

Key Figures

Vaccine target precision: 89% Gross ATM proceeds: $2.2 million Net loss: $3.5 million +2 more
Vaccine target precision
89%
EVX-01
Gross ATM proceeds
$2.2 million
Raised through the ATM equity program
Net loss
$3.5 million
Q3 2026; compared with a $3.7 million loss in Q2 2026 and $4.6 million profit in Q3 2025
Cash and cash equivalents
$13.3 million
As of September 30, 2026
Cash runway
Towards the end of 2027
Runway extension reported with Q3 2026 results

Previous Earnings Reports

2 past events · Latest: Aug 20
Same Type 2 events
  1. Aug 20

    Q2 2026 earnings

    24h Move
    +4.1%

    Reported a $3.7 million net loss, runway into H2 2027, and pipeline updates.

  2. Nov 06

    Q3 2025 earnings

    24h Move
    +10.6%

    Reported $7.5 million revenue and $4.6 million net income, including EVX-B3 licensing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

neoantigens, endogenous retrovirus (erv), ind-enabling studies, at-the-market (atm) equity program
4 terms
neoantigens medical
"against tumor-specific neoantigens."
Neoantigens are new protein fragments that appear on the surface of diseased cells, most often cancer cells, because of changes in their DNA; the immune system can recognize these as foreign. For investors, neoantigens matter because they are targets for precision therapies and vaccines that aim to teach the immune system to attack only diseased cells—think of them as unique fingerprints that enable treatments to be more specific and potentially more effective, which can drive clinical and commercial value.
endogenous retrovirus (erv) medical
"multiple non-conventional endogenous retrovirus (ERV) tumor antigens"
Endogenous retroviruses (ERVs) are viral DNA sequences that became part of an organism’s genome long ago and now sit like fossilized pages inside the body’s instruction manual. They can influence how nearby genes behave or become reactivated in disease, so they matter to investors because they can create new diagnostic markers, drug targets, or safety considerations for genetic and infectious-disease therapies, affecting clinical prospects and regulatory review.
ind-enabling studies regulatory
"continue to advance preclinical IND-enabling studies"
Ind-enabling studies are early research efforts that test whether a new drug or treatment is safe and effective enough to move forward in development. They are like preliminary tests to ensure a product works as intended before investing more resources into large-scale trials. For investors, these studies are important because successful results can signal potential progress toward bringing a new product to market, impacting its future value.
at-the-market (atm) equity program financial
"through utilization of our At-The-Market (ATM) equity program"
An at-the-market (ATM) equity program lets a company sell newly issued shares directly into the open market over time at the current trading price through a broker, rather than all at once. Think of it like drip-feeding new product into a store at whatever the going price is; it provides flexible, immediate fundraising but can reduce each existing shareholder’s ownership percentage and influence trading supply and share price, so investors watch how much and how often the company uses it.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

COPENHAGEN, Denmark, November 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, provides strategy and business update and announces third quarter 2026 financial results.

Strategy update
Evaxion is refocusing its strategy to prioritize its immuno-oncology assets and capabilities, fully leveraging AI-Immunology™ in novel cancer target discovery and cancer vaccine development.

The aim is to maximize the value given clinical validation of the platform in personalized cancer vaccines with EVX-01 and the broader opportunity with off-the-shelf cancer vaccines in multiple indications through access to a wider diversity of novel antigens, including but not limited to endogenous retroviruses (ERVs).

Going forward, Evaxion will focus its R&D portfolio by:

  • Advancing off-the-shelf cancer vaccines EVX-04 and EVX-05 towards clinical development
  • Expanding personalized cancer vaccine EVX-01’s potential in multiple indications via partnerships
  • Continuing to identify new cancer vaccine targets for further development by mining novel sources from the dark genome
  • Working through partnerships on our preclinical portfolio of infectious disease assets
  • Completing validation on the autoimmune concepts we have developed with AI-Immunology™ for future partnerships

As a result of the refocused strategy, Evaxion will make some adjustments to its organization.

“We are refocusing our strategy on the unique capabilities of AI-Immunology™ in discovery and design of novel cancer vaccines. Evaxion’s AI-Immunology™ platform has recently been further validated by stronger clinical and translational datasets from the phase 2 trial with EVX-01 in advanced melanoma at a time when the entire landscape around personalized cancer vaccines has changed more positively. With the ability to also produce off-the-shelf cancer vaccines, we are maintaining strong operational momentum on all of our milestones for the year, tracking towards achieving the last one with the EVX-04 off-the-shelf vaccine clinical trial submission, as we re-focus our efforts towards immuno-oncology”, says Helen Tayton-Martin, CEO of Evaxion.

Business highlights (since last quarterly update)

  • Presentation of three-year clinical outcome and immune data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 and additionally new phase 2 biomarker data at SITC 2026
  • Announcing the upcoming presentation of new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), at the ASH 2026 Meeting
  • Winning the 2026 International Prix Galien Award for Best digital health solution for AI-Immunology™
  • Our cash runway has been extended towards the end of 2027

Conference call and webcast
Evaxion’s executive management will host a conference call and webcast at 8.30am ET/14.30 CET today, presenting the business update and financial results as well as taking questions.

To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event.

To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event.

Research & Development (R&D) update
Evaxion has a R&D pipeline of innovative vaccine candidates for both cancer and infectious diseases and has recently made progress in both areas.

Most notably, we have presented new phase 2 data for personalized cancer vaccine EVX-01, our most advanced pipeline asset, at both the European Society for Medical Oncology (ESMO) and Society for Immunotherapy of Cancer (SITC) congresses.

Designed with our AI-Immunology™ platform, EVX-01 is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient's immune system to attack the cancer by mounting a targeted response against tumor-specific neoantigens.

EVX-01 is intended for first-line treatment of multiple advanced solid cancer tumors and has, in the phase 2 trial, been evaluated as a treatment of advanced melanoma. The recent data shows an 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up.

The very high precision rate is another confirmation that AI-Immunology™ identifies and selects the most therapeutically relevant vaccine targets. Thus, the new data supports both EVX-01 as a promising personalized cancer vaccine and AI-Immunology™ as a validated technology for discovery and design of novel cancer treatments.

Further to the personalized approach, we are leveraging AI-Immunology™ to develop novel off-the-shelf cancer vaccines, including EVX-04 targeting AML. Developed with AI-Immunology™, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome.

We are on track to file the application for a phase 1 trial with EVX-04 before the end of the year and continue to advance preclinical IND-enabling studies and expand the data package. We are very much looking forward to presenting new target validation data for EVX-04 at the important American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, Louisiana, December 12-15, 2026.

Within infectious diseases we have achieved the milestone of designing and preclinically validating antigens to be included in EVX-B4, a novel vaccine candidate for Group A Streptococcus. As per our refocused strategy, we will only conduct future work on our infectious disease programs if funded by external partners and will continue to proactively pursue relevant partnership opportunities.

We have also recently presented AI-Immunology™ derived novel therapeutic concepts for autoimmune diseases. Our future activities in this space will be focused on concept validation for potential future partnerships.

Business development update
We remain active in multiple parallel partnership discussions based on external interest in both AI-Immunology™ and our R&D pipeline based on the strong clinical validation of our platform and as we continue to pursue our strategy of developing novel IO assets and strengthening our platform through strategic partnerships.

We were honored to receive the prestigious International Prix Galien Award for AI-Immunology™ as best digital health solution in October. The award is another strong external validation and recognition of the AI-Immunology™ platform in generating key data confirming the fact that AI-Immunology™ is a platform that delivers meaningful therapeutic product candidates. This is an important distinction with potential business partners.

Third quarter 2026 financial results
We have extended our cash runway towards the end of 2027 through utilization of our At-The-Market (ATM) equity program selling Evaxion shares resulting in gross proceeds of $2.2 million improving our cash at hand and equity.

Earlier in November, we filed an amendment to the registration statement on Form F-1 related to the 2025 debt settlement agreement with The European Investment Bank (EIB) with the US Securities and Exchange Commission.

The registration statement was originally filed in November 2025, as required under the agreement under which EIB converted debt to warrants, and relates solely to the possible resale by EIB of shares issuable upon exercise of those warrants. We are not conducting a capital raise.

The financial results for the third quarter 2026 were in line with expectations with a net loss of $3.5 million, compared to loss of $3.7 million in the second quarter 2026 and a profit of $4.6 million in the third quarter 2025.

Compared to same period last year where we recorded revenue from out-licensing EVX-B3 to MSD, no revenue has been recorded in Q3 2026, while we have reduced cost in the quarter compared to last year primarily relating to lower personnel expenses and capital market costs, and our net financial expenses reflects normalized financial income and expenses.

Research and development (R&D) expenses were $2.3 million for the third quarter 2026, aligned with second quarter 2026, and a reduction compared to third quarter last year, mainly due to reduced headcount.

General and administrative (G&A) expenses were $1.4 million for the quarter, level with second quarter 2026, and compared to $1.4 million in second quarter 2025. Compared to last year we have lower capital market cost compensated by higher business development costs.

Net financial expense of $0.1 million for the third quarter 2026 compared to net financial income of $1.3 million same quarter last year. The third quarter 2026 reflects our normalized business, and where Q3 last year was impacted by financial income from debt settlement agreement with EIB and financial expenses from a significant higher derivative liability.

Cash and cash equivalents as of September 30, 2026, were $13.3 million, compared to $14.0 million as of June 30, 2026, extending our current cash runway towards the end of 2027.

Total equity amounts to $8.1 million as of September 30, 2026, reflecting the net loss of the first nine months of 2026 and added the proceeds from ATM sales, when compared to $17.0 million as of December 31, 2025.

Evaxion A/S
(Unaudited) Consolidated statement of financial position data
(USD in thousands)

 Sep 30,
2026
Dec 31,
2025
Cash and cash equivalents13,27423,234
Total assets18,66528,408
Total liabilities10,52311,369
Share capital17,12915,791
Other reserves130,301127,492
Accumulated deficit(139,288)(126,244)
Total equity8,14317,039
Total liabilities and equity18,66528,408


Evaxion A/S
(Unaudited) Consolidated statement of comprehensive loss data
(USD in thousands, except per share data)

 Three Months Ended
Sep 30,
Nine Months Ended
Sep 30,
 2026202520262025
Revenue-7,492-7,528
Research and development(2,312)(3,092)(6,943)(7,415)
General and administrative(1,361)(1,377)(4,394)(5,295)
Operating profit/(loss)(3,673) 3,022(11,338) (5,182)
Finance income1522,6905575,729
Finance expenses(212)(1,360)(730)(2,988)
Net profit/(loss) before tax(3,732) 4,352(11,511) (2,442)
Income tax benefit191265611652
Net profit/(loss) for the period(3,541) 4,618(10,899) (1,789)
Net loss attributable to shareholders of Evaxion A/S(3,541) 4,618(10,899) (1,789)
Loss per share – basic and diluted(0.01)0.01(0.03)(0.01)
Number of shares used for calculation (basic and diluted)431,856,012318,041,649422,013,554289,792,967


Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering clinical-stage TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. Evaxion harnesses the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer. Through partnerships AI-Immunology™ can also be applied in infectious and autoimmune diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.

We have developed a pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was Evaxion’s net loss in the third quarter of 2026?

Evaxion posted a $3.5 million net loss in the third quarter of 2026. That compares with a $3.7 million loss in the second quarter of 2026 and a $4.6 million profit in the third quarter of 2025.

What is Evaxion prioritizing in its revised research strategy?

Evaxion is prioritizing cancer vaccine development, with plans to move off-the-shelf candidates EVX-04 and EVX-05 toward clinical development and pursue partnerships to expand personalized vaccine candidate EVX-01 into additional indications.

Is Evaxion raising capital through its November Form F-1 amendment?

The Form F-1 amendment does not raise capital for Evaxion. It relates solely to the possible resale by the European Investment Bank of shares issuable if the bank exercises warrants from its 2025 debt settlement with Evaxion.

Keep reading